Inositol treatment inhibits medulloblastoma through suppression of epigenetic-driven metabolic adaptation

Sara Badodi; Nicola Pomella; Xinyu  Zhang; Gabriel Rosser; John  Whittingham; Maria Niklison Chirou; Yau Mun Lim; Sebastian Brandner; Gillian  Morrison; Steven M. Pollard; Christopher D. Bennett; Steven C. Clifford; Andrew Peet; Albert Basson; Silvia Marino

doi:10.1038/s41467-021-22379-7

Inositol treatment inhibits medulloblastoma through suppression of epigenetic-driven metabolic adaptation

Sara Badodi, Nicola Pomella, Xinyu Zhang, Gabriel Rosser, John Whittingham, Maria Niklison Chirou, Yau Mun Lim, Sebastian Brandner, Gillian Morrison, Steven M. Pollard, Christopher D. Bennett, Steven C. Clifford, Andrew Peet, Albert Basson, Silvia Marino

Department of Life Sciences

Research output: Contribution to journal › Article › peer-review

21 Citations (SciVal)

Abstract

Deregulation of chromatin modifiers plays an essential role in the pathogenesis of medulloblastoma, the most common paediatric malignant brain tumour. Here, we identify a BMI1-dependent sensitivity to deregulation of inositol metabolism in a proportion of medulloblastoma. We demonstrate mTOR pathway activation and metabolic adaptation specifically in medulloblastoma of the molecular subgroup G4 characterised by a BMI1High;CHD7Low signature and show this can be counteracted by IP6 treatment. Finally, we demonstrate that IP6 synergises with cisplatin to enhance its cytotoxicity in vitro and extends survival in a pre-clinical BMI1High;CHD7Low xenograft model.

Original language	English
Article number	2148
Number of pages	16
Journal	Nature Communications
Volume	12
Issue number	1
DOIs	https://doi.org/10.1038/s41467-021-22379-7
Publication status	Published - 12 Apr 2021

Bibliographical note

Funding Information:
We are grateful to the BSU staff for help in the daily care of our mouse colony and to the Blizard Core Facilities (Imaging and FACS) for technical advice. Access to medulloblastoma tissue was obtained through the CCLG tissue bank (project number 2015 BS 05). This work is supported by grants of the Medical Research Council UK (MR/ N000528/1) to S.M. and M.A.B. and a Brain Tumour Research Centre of Excellence award to S.M. Y.M.L. is funded by a Cancer Research UK Accelerator grant Cl 15121A 20256. Funding from Children with Cancer UK (15/188), Action Medical Research and The Brain Tumour Charity (GN2181) to C.D.B., S.C.C. and A.P. are also acknowledged. A.P. was funded by an NIHR Research Professorship (NIHR-RP-R2-12-019). S.Br. is partly supported by the Department of Health’s NIHR Biomedical Research Centre’s funding scheme to University College London Hospitals.

Data availability
The authors declare that all the data supporting the findings of this study are available
within the article and its Supplementary Information files. The datasets generated in this
study and processed data are available in the NCBI Gene Expression Omnibus database
(GSE156077) or are available from the corresponding author upon reasonable request.
Publicly available datasets used in the study: GSE85217 (Expression data from primary
medulloblastoma samples), Reactome (https://reactome.org/), Panther Gene Ontology
tool (http://geneontology.org/), Swiss-Prot (https://www.uniprot.org/statistics/SwissProt), PhosphoSite (https://www.phosphosite.org/), Phospho.ELM (http://phospho.elm.
eu.org/) and PhosphoPOINT (http://kinase.bioinformatics.tw/). Source data are provided
with this paper.

Access to Document

10.1038/s41467-021-22379-7Licence: CC BY

Cite this

Badodi, S., Pomella, N., Zhang, X., Rosser, G., Whittingham, J., Niklison Chirou, M., Lim, Y. M., Brandner, S., Morrison, G., Pollard, S. M., Bennett, C. D., Clifford, S. C., Peet, A., Basson, A., & Marino, S. (2021). Inositol treatment inhibits medulloblastoma through suppression of epigenetic-driven metabolic adaptation. Nature Communications, 12(1), Article 2148. https://doi.org/10.1038/s41467-021-22379-7

Badodi, S, Pomella, N, Zhang, X, Rosser, G, Whittingham, J, Niklison Chirou, M, Lim, YM, Brandner, S, Morrison, G, Pollard, SM, Bennett, CD, Clifford, SC, Peet, A, Basson, A & Marino, S 2021, 'Inositol treatment inhibits medulloblastoma through suppression of epigenetic-driven metabolic adaptation', Nature Communications, vol. 12, no. 1, 2148. https://doi.org/10.1038/s41467-021-22379-7

@article{c3d883c6c9234be8b52f9827ca228be5,

title = "Inositol treatment inhibits medulloblastoma through suppression of epigenetic-driven metabolic adaptation",

abstract = "Deregulation of chromatin modifiers plays an essential role in the pathogenesis of medulloblastoma, the most common paediatric malignant brain tumour. Here, we identify a BMI1-dependent sensitivity to deregulation of inositol metabolism in a proportion of medulloblastoma. We demonstrate mTOR pathway activation and metabolic adaptation specifically in medulloblastoma of the molecular subgroup G4 characterised by a BMI1High;CHD7Low signature and show this can be counteracted by IP6 treatment. Finally, we demonstrate that IP6 synergises with cisplatin to enhance its cytotoxicity in vitro and extends survival in a pre-clinical BMI1High;CHD7Low xenograft model.",

author = "Sara Badodi and Nicola Pomella and Xinyu Zhang and Gabriel Rosser and John Whittingham and {Niklison Chirou}, Maria and Lim, {Yau Mun} and Sebastian Brandner and Gillian Morrison and Pollard, {Steven M.} and Bennett, {Christopher D.} and Clifford, {Steven C.} and Andrew Peet and Albert Basson and Silvia Marino",

note = "Funding Information: We are grateful to the BSU staff for help in the daily care of our mouse colony and to the Blizard Core Facilities (Imaging and FACS) for technical advice. Access to medulloblastoma tissue was obtained through the CCLG tissue bank (project number 2015 BS 05). This work is supported by grants of the Medical Research Council UK (MR/ N000528/1) to S.M. and M.A.B. and a Brain Tumour Research Centre of Excellence award to S.M. Y.M.L. is funded by a Cancer Research UK Accelerator grant Cl 15121A 20256. Funding from Children with Cancer UK (15/188), Action Medical Research and The Brain Tumour Charity (GN2181) to C.D.B., S.C.C. and A.P. are also acknowledged. A.P. was funded by an NIHR Research Professorship (NIHR-RP-R2-12-019). S.Br. is partly supported by the Department of Health{\textquoteright}s NIHR Biomedical Research Centre{\textquoteright}s funding scheme to University College London Hospitals. Data availability The authors declare that all the data supporting the findings of this study are available within the article and its Supplementary Information files. The datasets generated in this study and processed data are available in the NCBI Gene Expression Omnibus database (GSE156077) or are available from the corresponding author upon reasonable request. Publicly available datasets used in the study: GSE85217 (Expression data from primary medulloblastoma samples), Reactome (https://reactome.org/), Panther Gene Ontology tool (http://geneontology.org/), Swiss-Prot (https://www.uniprot.org/statistics/SwissProt), PhosphoSite (https://www.phosphosite.org/), Phospho.ELM (http://phospho.elm. eu.org/) and PhosphoPOINT (http://kinase.bioinformatics.tw/). Source data are provided with this paper.",

year = "2021",

month = apr,

day = "12",

doi = "10.1038/s41467-021-22379-7",

language = "English",

volume = "12",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - Inositol treatment inhibits medulloblastoma through suppression of epigenetic-driven metabolic adaptation

AU - Badodi, Sara

AU - Pomella, Nicola

AU - Zhang, Xinyu

AU - Rosser, Gabriel

AU - Whittingham, John

AU - Niklison Chirou, Maria

AU - Lim, Yau Mun

AU - Brandner, Sebastian

AU - Morrison, Gillian

AU - Pollard, Steven M.

AU - Bennett, Christopher D.

AU - Clifford, Steven C.

AU - Peet, Andrew

AU - Basson, Albert

AU - Marino, Silvia

N1 - Funding Information: We are grateful to the BSU staff for help in the daily care of our mouse colony and to the Blizard Core Facilities (Imaging and FACS) for technical advice. Access to medulloblastoma tissue was obtained through the CCLG tissue bank (project number 2015 BS 05). This work is supported by grants of the Medical Research Council UK (MR/ N000528/1) to S.M. and M.A.B. and a Brain Tumour Research Centre of Excellence award to S.M. Y.M.L. is funded by a Cancer Research UK Accelerator grant Cl 15121A 20256. Funding from Children with Cancer UK (15/188), Action Medical Research and The Brain Tumour Charity (GN2181) to C.D.B., S.C.C. and A.P. are also acknowledged. A.P. was funded by an NIHR Research Professorship (NIHR-RP-R2-12-019). S.Br. is partly supported by the Department of Health’s NIHR Biomedical Research Centre’s funding scheme to University College London Hospitals. Data availability The authors declare that all the data supporting the findings of this study are available within the article and its Supplementary Information files. The datasets generated in this study and processed data are available in the NCBI Gene Expression Omnibus database (GSE156077) or are available from the corresponding author upon reasonable request. Publicly available datasets used in the study: GSE85217 (Expression data from primary medulloblastoma samples), Reactome (https://reactome.org/), Panther Gene Ontology tool (http://geneontology.org/), Swiss-Prot (https://www.uniprot.org/statistics/SwissProt), PhosphoSite (https://www.phosphosite.org/), Phospho.ELM (http://phospho.elm. eu.org/) and PhosphoPOINT (http://kinase.bioinformatics.tw/). Source data are provided with this paper.

PY - 2021/4/12

Y1 - 2021/4/12

N2 - Deregulation of chromatin modifiers plays an essential role in the pathogenesis of medulloblastoma, the most common paediatric malignant brain tumour. Here, we identify a BMI1-dependent sensitivity to deregulation of inositol metabolism in a proportion of medulloblastoma. We demonstrate mTOR pathway activation and metabolic adaptation specifically in medulloblastoma of the molecular subgroup G4 characterised by a BMI1High;CHD7Low signature and show this can be counteracted by IP6 treatment. Finally, we demonstrate that IP6 synergises with cisplatin to enhance its cytotoxicity in vitro and extends survival in a pre-clinical BMI1High;CHD7Low xenograft model.

AB - Deregulation of chromatin modifiers plays an essential role in the pathogenesis of medulloblastoma, the most common paediatric malignant brain tumour. Here, we identify a BMI1-dependent sensitivity to deregulation of inositol metabolism in a proportion of medulloblastoma. We demonstrate mTOR pathway activation and metabolic adaptation specifically in medulloblastoma of the molecular subgroup G4 characterised by a BMI1High;CHD7Low signature and show this can be counteracted by IP6 treatment. Finally, we demonstrate that IP6 synergises with cisplatin to enhance its cytotoxicity in vitro and extends survival in a pre-clinical BMI1High;CHD7Low xenograft model.

UR - http://www.scopus.com/inward/record.url?scp=85104230479&partnerID=8YFLogxK

U2 - 10.1038/s41467-021-22379-7

DO - 10.1038/s41467-021-22379-7

M3 - Article

SN - 2041-1723

VL - 12

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 2148

ER -

Inositol treatment inhibits medulloblastoma through suppression of epigenetic-driven metabolic adaptation

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Ultra High Pressure Liquid Chromatography coupled to a UV detector (UPLC-UV)

Cite this

Inositol treatment inhibits medulloblastoma through suppression of epigenetic-driven metabolic adaptation

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Equipment

Ultra High Pressure Liquid Chromatography coupled to a UV detector (UPLC-UV)

Cite this